An autopsy case of drug-induced diffuse cerebral axonopathic leukoencephalopathy: the pathogenesis in relation to reversible posterior leukoencephalopathy syndrome

Neuropathology. 2007 Aug;27(4):364-70. doi: 10.1111/j.1440-1789.2007.00771.x.

Abstract

An autopsy case of diffuse axonopathic leukoencephalopathy induced by drug treatment is reported. A 70-year-old woman with multiple myeloma developed encephalopathy several days after completing a course of intravenous human immunoglobulin (IVIg) and granulocyte-colony stimulating factor (G-CSF), and died within I month. T2-weighted MRI demonstrated multifocal high-signal areas in the bilateral cerebral white matter, especially in the right frontal lobe. Neuropathologically, multifocal hydropic axonal swelling with a poor glial reaction was recognized diffusely in the bilateral deep cerebral white matter, being especially marked in the frontal lobe. The cortex, subcortical U-fibers, corpus callosum, and anterior commissure were spared. The cerebellar white matter also showed similar changes, albeit less marked, but the brainstem was spared. Microscopically, the myeloma involvement of the CNS was limited to the dura, and the cerebral arteries showed slight atherosclerosis, but neither thrombi nor angitis. This case, although ultimately fatal, neurologically and neuroradiologically resembled reversible posterior leukoencephalopathy syndrome (RPLS) induced by IVIg and/or G-CSF, and the nature and selective distribution of the neuropathological changes suggested that the pathogenesis involved vasospasm of the bilateral internal carotid artery and the main trunks of the cerebral arteries, due to unknown cause, inducing ischemia in the deep white matter, which is supplied by long nutrient arteries.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Autopsy
  • Brain Diseases / chemically induced*
  • Brain Diseases / pathology*
  • Brain Diseases / physiopathology
  • Fatal Outcome
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / adverse effects*
  • Humans
  • Immunoglobulins, Intravenous / adverse effects*
  • Magnetic Resonance Imaging
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology

Substances

  • Immunoglobulins, Intravenous
  • Granulocyte-Macrophage Colony-Stimulating Factor